Skip to content

Second Line Treatment of Knee Osteochondral Lesion With Treated Osteochondral Graft

Second Line Treatment of Knee Osteochondral Lesion With Decellularized Treated Osteochondral Allograft. Phase IIa Trial

Status
Terminated
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02430558
Acronym
ODPHOENIX2
Enrollment
10
Registered
2015-04-30
Start date
2016-04-05
Completion date
2021-06-15
Last updated
2022-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cartilage Injury

Brief summary

Patient with IKDC score \< 65, pretreated with mosaicplasty or ACI ( with matrix or not) within \> 18 months, with one or two osteochondral lesions are recruited to have treated osteochondral allografts in mosaicplasty.

Interventions

BIOLOGICALOD-PHOENIX

Decellularized, freeze-dried, irradiated osteochondral allograft

Sponsors

TBF Genie Tissulaire
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Male and female patients between the ages of 18 and 55 * osteochondral lesions of the knee due to trauma or osteochondritis dissecans or removal treatment ( lesion post autograft) * Osteochondral lesion \> grade II- ICRS * One lesion or 2 concomitant lesions (tibial plateau, patella and condyles )at least one lesion has been pretreated by mosaicplasy or ACI. These treatment would have to have been made at least 18 months before inclusion * Presence of disabling and clinically meaningful symptoms (subjective IKDC \< 65, no improvement for 3 months) * No significant obesity (BMI \< 30) * Accompanying ligamentous and meniscal lesions, joint malalignment and patella femoral instability are authorized and corrected concurrently. * Patient able to understand, sign and date the informed consent form * Patient affiliated with a national health insurance system or who is the beneficiary of such as system * Women of childbearing age may not be included in the clinical trial unless their pregnancy test is negative. If this test is negative, they will be asked to use an effective birth control method during the entire the study.

Exclusion criteria

* \- Pregnant or breast feeding women: Women of childbearing age will be asked to undergo a pregnancy test before being enrolled into the study and to use an effective birth control method. * Presence of osteoarthritis, rheumatoid arthritis, any other condition of knee joint that, in the surgeon's opinion, is likely to compromise the allograft's outcome * Excessive laxity or recurrent instability that could affect the score evaluation without concomitant ligamentoplasty * Presence of an ulcerative disease, heavy smoking, tuberculosis, chronic psychiatric disorder or disease requiring long-term treatment with a medication that would affect bone or joint metabolism * Persons with cancer or a history of cancer * Persons deprived of their freedom by a judicial or administrative decision * Adults subject to legal protection measures or who are unable to provide their consent

Design outcomes

Primary

MeasureTime frame
improvement of IKDC score18 months

Secondary

MeasureTime frameDescription
Knee Injury and Osteoarthritis Outcome Score (KOOS)18 months
recellularization of tissue (arthroscopy and histology)18 monthsarthroscopy and histology
integration of the tissue by imagery18 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026